Tools
Stock profile

BillionToOne, Inc. (BLLN)

BLLN · Latest close $91.54 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$91.54
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
2
vs previous quarter

BillionToOne, Inc. (BLLN) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $26.7M sold). Latest close $91.54 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 2, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-26.7M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Perceptive Advisors · Polen Capital Management — 2 tracked funds hold BLLN. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 96 sales ($26.7M). Insider trading

Often held alongside

Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · QUEST DIAGNOSTICS INC (DGX) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Perceptive Advisors0.16%86,812TRIMMED (-5.4%) Q3 filed Nov 16
Polen Capital Management0.02%16,975NEW Q3 filed Nov 13
Deep Track Capital——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -20.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

149.9760.592025-11-062026-11-18

Closing prices (unadjusted for dividends), last 2 years — 260 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding157 of 8,857 filers
Long-only filers among them156
Change vs 2026 Q1+71 net · 155 entered · 84 exited
Shares reported, all filers15,278,720
Reported value, all filers$1.7B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryServices-Medical Laboratories (SIC 8071)
Revenue · FY2025$305.1M
Net income · FY2025$7.5M
Total assets · FY2025$632.7M
Shares outstanding11,178,467
Market cap (at latest close)$1.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Sep 30, 2025.

Short interest

Shares short · Oct 15, 20262,932,232
Share of shares outstanding26.23%
Days to cover5.53

Shares short at recent settlements — Jul 31, 2026: 1.9M · Aug 14, 2026: 1.9M · Aug 31, 2026: 2.3M · Sep 15, 2026: 2.6M · Sep 30, 2026: 2.8M · Oct 15, 2026: 2.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Sep 30, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 746 · Aug 31, 2026: 1K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Sep 30, 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 96 sales by 4 insiders ($26.7M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 2, 2026Atay OguzhanChairman and CEOSell1,482$107.31$159.0KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell4,009$108.25$434.0KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell5,720$109.08$623.9KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell3,803$110.29$419.4KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell1,117$110.98$124.0KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell536$112.44$60.3KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell974$107.34$104.5KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell2,075$108.43$225.0KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell2,451$109.11$267.4KSEC filing
Nov 2, 2026Atay OguzhanChairman and CEOSell2,223$110.35$245.3KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 5, 2026Tsao DavidOfficer, Director20,000$2.2MOct 5, 2026SEC filing
Oct 5, 2026ten Bosch John RoderickOfficer2,834$298.0KOct 5, 2026SEC filing
Oct 5, 2026Tsao DavidOfficer, Director1,750$184.0KOct 5, 2026SEC filing
Sep 28, 2026Atay OguzhanMember of immediate family of any of the foregoing2,666$321.6KSep 28, 2026SEC filing
Sep 28, 2026Atay OguzhanOfficer, Director8,333$1.0MSep 28, 2026SEC filing
Sep 24, 2026Tsao DavidOfficer, Director3,333$416.6KSep 24, 2026SEC filing
Sep 24, 2026ten Bosch John RoderickOfficer1,416$169.9KSep 24, 2026SEC filing
Sep 21, 2026ten Bosch John RoderickOfficer1,416$151.0KSep 21, 2026SEC filing
Sep 17, 2026Lynch Thomas P.Officer35,112$3.9MSep 17, 2026SEC filing
Sep 14, 2026Atay OguzhanOfficer, Director24,999$2.5MSep 14, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jan 20, 2026SCHEDULE 13D+15.9% (close Jan 21, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jan 21, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Feb 17, 2026David TsaoSC 13G3,035,7676.9%Dec 31, 2025SEC filing
Feb 17, 2026Oguzhan AtaySC 13G3,206,8617.3%Dec 31, 2025SEC filing
Feb 13, 2026NeoTribe Ventures I, L.P. ("NTV I")SC 13G2,710,2866.6%Nov 7, 2025SEC filing
Jan 20, 2026Hummingbird Ventures Management NVSC 13D7,887,23719.6%Nov 6, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Services-Medical Laboratories (SIC 8071). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Financial Screens

· Piotroski — Financial health improved over the past year

Key figures

· Piotroski — F-score: 7 · Return on assets: 1.2% · Operating cash flow: $24.6M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q4, ranked #7 of 50.

Also held by the tracked funds that hold BLLN — ranked by lift, the co-holding pattern described in Methodology: Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · QUEST DIAGNOSTICS INC (DGX) · EXAGEN INC. (XGN) · CareDx, Inc. (CDNA) · HCA Healthcare, Inc. (HCA).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jun 29, 20261.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Natera, Inc. (NTRA) · Track Record: how the signals scored · Practice timing on BLLN

One email a week: the week’s new filings and research. Subscribe free

← BLK  ·  BLMN →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.